"The preclinical data for REM-422 provide strong therapeutic rationale for our ongoing Phase I study in AML and High-Risk MDS," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback